B. Braun Receives FDA Approval of Daytona Beach Pharmaceutical Manufacturing Site
- B.Braun Medical, Inc.
BETHLEHEM, Pa., Jan. 28, 2022 /PRNewswire/ — B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, today announced that the company has received final approval by the U.S. Food & Drug Administration (FDA) for its new pharmaceutical manufacturing plant in Daytona Beach, FL. The site will produce 0.9% Sodium Chloride for Injection available in B. Braun’s Excel® Plus IV Bags in 1,000 mL and 500 mL sizes. Consistent with B. Braun’s decades-long commitment to protect patients from exposure to harmful chemicals, the Excel Plus IV bags are not made with PVC, DEHP or natural rubber latex. Read more…
Related Reading
Event / Regulatory Affairs
Medical Device Submissions Workshops – Premarket Approval (PMA)
8:30 am – 4:30 pm ET
February 6-7, 2025
Our in-depth device submissions workshops will provide real-world case studies, tips and best practices directly from FDA and industry experts.
Event / Regulatory Affairs
Medical Device Submissions Workshops – Investigational Device Exemption (IDE)
8:30 am – 5:15 pm ET
February 5, 2025
Our in-depth device submissions workshops will provide real-world case studies, tips and best practices directly from FDA and industry experts.
Resource / Global & Trade / Supply Chain
EY 18th annual Pulse of the MedTech Industry Report
October 25, 2024
The 18th annual Pulse of the MedTech Industry report finds the medical technology industry continuing to push at new frontiers, as ongoing breakthroughs in MedTech AI and renewed hope for MedTech M&A hold out the possibility of making devices smarter, smaller and more personalized.
News / Global & Trade
AdvaMed Welcomes India, New Member Countries from Latin America, Middle East, Africa to IMDRF
October 10, 2024
The International Medical Device Regulators Forum (IMDRF) consists of medical device regulators from around the world that voluntarily convene to harmonize the regulatory requirements for medical products varying from country to country. The U.S. FDA is the Chair and Secretariat of the IMDRF for 2024 and recently hosted its 26th session. The IMDRF added 15 new affiliate members this year (Botswana, Costa Rica, Dominican Republic, El Salvador, Ethiopia, Kenya, India, Jordan, México, Oman, Nigeria, Paraguay, Peru, Tanzania, and Zimbabwe).
News / Code of Ethics / Global & Trade
AdvaMed Welcomes APEC Recommendations for Enterprise Integrity and Public Procurement
September 23, 2024
Event / China / Regulatory Affairs
China Regulatory Workshop
November 19, 2024 | 11:30 AM – 6:30 PM PT November 20, 2024 | 8:15 AM – 4:00 PM PT
Get the latest on new policy updates and guidance for the clinical evaluation of medical devices.
Event / Regulatory Affairs
Medical Device Submissions Workshops – 510(k) and De Novo
8:30 am – 4:15 pm ET
February 3-4, 2025
Our in-depth device submissions workshops will provide real-world case studies, tips and best practices directly from FDA and industry experts.
News / Regulatory Affairs
Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
July 31, 2024
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Shield™ blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease.